AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04547699 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: A single step culture medium
Description: A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK
Study NCT04547699 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: A single step culture medium
Description: A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK
Study NCT03479554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment
Description: The CATIS 2 trial is designed to test BP reduction strategies-early antihypertensive treatment vs. delayed antihypertensive treatment-rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial.~BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:~* Step 1 (within 24 hours after randomization): To lower systolic BP by 10-20% with an average of 15% (but systolic BP not lower than 130 mmHg and diastolic BP not lower than 80 mmHg) within the first 24 hours after randomization based on the participant's admission BP levels.~* Step 2 (within 7 days after randomization): To achieve systolic BP below 140 mmHg (but not lower than 120 mmHg) and diastolic BP below 90 mmHg (but not lower than 70 mmHg) and maintain this BP level afterward.
Study NCT03479554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed antihypertensive treatment
Description: All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP \<140 mmHg (but not lower than 120 mmHg) and diastolic BP \<90 mmHg (but not lower than 70 mmHg) in two weeks. A BP check-up visit will be conducted in two weeks. If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.
Study NCT04497623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours
Description: Recruited patients will receive volume-controlled mechanical ventilation (assist-control mode) using the Unisabana-Herons ventilator for 24 hours. Information on clinical, hemodynamic, and respiratory variables will be recorded from 30 minutes before the start of mechanical ventilation with the Unisabana-Herons ventilator. Recordings will be made in the first 4 hours every 15 minutes in the CFR, except for arterial blood gases which will be taken every 30 minutes. In the following 20 hours, arterial blood gas controls will be taken at hour 12 from the start of the ventilator and at hour 24. Other hemodynamic and respiratory variables will be recorded every hour from hour 4 of ventilator start until hour 24.
Study NCT01383148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4010
Description: TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.~Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.~First line therapy:~* Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab~* Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin~Maintenance therapy:~• Pemetrexed or erlotinib for eligible patients and according to labeling.
Study NCT01383148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~* First line therapy: as in Arm 1~* Maintenance therapy: as in Arm 1
Study NCT04130269 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Questionnaires, lab-run
Study NCT00850577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Solution, IV, 200 mg/m2, Q21days, 6 cycles
Study NCT02212184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Diaphragm Release Technique
Description: The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
Study NCT00850577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Solution, IV, AUC=6, Q21days, 6 cycles
Study NCT00850577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-322
Description: Solution, IV, 2 mg/kg, Q7days, Until PD
Study NCT02212184 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual Diaphragm release technique (sham)
Description: Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
Study NCT00850577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Solution, IV, 15 mg/kg, Q21days, Until PD
Study NCT00850577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab placebo (ie saline solution)
Description: Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
Study NCT00452569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
Study NCT00929643 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: success of the initial empiric treatment
Study NCT00740857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 placebo gels capsules delivered as a single dose.
Study NCT00740857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen Formulation 1
Description: 2 marketed ibuprofen gels
Study NCT00740857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen Formulation 2
Description: 2 marketed ibuprofen gels
Study NCT04039009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvic Organ Prolapse Quantification system
Description: The Pelvic Organ Prolapse Quantification system assessment tool measures nine anatomical points and distances in the vagina. The hymen is the reference point to which the other points are compared. The prolapsed organs are measured in centimeters to the hymen with an examination ruler.
Study NCT00452569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
Study NCT04121143 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IL-17A Antagonist
Description: SHR-1314 subcutaneous injection
Study NCT03791944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3DV+TPS/VARIAN
Description: Use imported 3DV+TPS to map targets and develop treatment plans
Study NCT03791944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TPS / VARIAN
Description: Use imported TPS to map targets and develop treatment plans
Study NCT03791944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3DV + TPS / Domestic Accelerator
Description: Use domestic 3DV+TPS to delineate target areas and develop treatment plans
Study NCT03791944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TPS / Domestic Accelerator
Description: Use domestic TPS to map targets and develop treatment plans
Study NCT04121143 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-17A Antagonist
Description: SHR-1314 subcutaneous injection
Study NCT04121143 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo subcutaneous injection to maintain consistency and to prevent blindness
Study NCT04121143 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: placebo subcutaneous injection to maintain consistency and to prevent blindness
Study NCT02701634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENTO
Description: Tablets administered orally
Study NCT04662515 — intervention group
Intervention type: PROCEDURE
Intervention: Type of surgery
Description: surgical or non-surgical extraction one or more teeth
Study NCT02701634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study NCT04662515 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Study NCT02765165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL311
Description: Administered once weekly in a 21-day cycle
Study NCT02765165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL311
Description: Administered once daily in a 21-day cycle
Study NCT02765165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL311
Description: Administered once daily in a 42-day cycle
Study NCT02765165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Administered once every 6 weeks in a 42-day cycle
Study NCT02511717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous tibial nerve stimulation
Description: Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
Study NCT02511717 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous tibial nerve stimulation
Description: Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
Study NCT04662515 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Study NCT02438579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal Irrigation & Gargling
Description: Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
Study NCT04096131 — intervention group
Intervention type: PROCEDURE
Intervention: cataract surgery
Description: phacoemulsification
Study NCT02026297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 gram IV over 10 minutes
Study NCT02026297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; Normal Saline
Description: 0.9% Normal Saline
Study NCT00300599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway pressure
Description: Continuous positive pressure device with a time clock
Study NCT00300599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03658525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR LINAC
Description: MR GUIDED PROSATE RADIOTHERAPY
Study NCT00481039 — intervention group
Intervention type: PROCEDURE
Intervention: Medical history and basic laboratory analysis
Description: Medical history and basic laboratory analysis
Study NCT00410163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab 500mg
Description: Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
Study NCT00410163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab 1000mg
Description: Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
Study NCT00410163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
Study NCT00410163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
Study NCT04158609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler flow indices assessment
Description: Doppler flow indices, UA-PI, MCA-PI and CPR values, assessment performed prior to induction of labor
Study NCT03318341 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Real Stimulation
Description: The device applies wrist vibration at a subthreshold (imperceptible) level.
Study NCT03318341 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Stimulation
Description: The device applies no vibration.
Study NCT00248053 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: curcumin
Description: curcumin 500 mg by mouth, three times a day for 9 months
Study NCT00439621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP 01
Description: Active immunotherapy
Study NCT00439621 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RP 01
Description: Active immunotherapy
Study NCT00769418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odanacatib
Description: Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days.
Study NCT00769418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days.
Study NCT03579667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: 12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
Study NCT02948400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pedestrian safety training in pedestrian virtual environment
Description: pedestrian safety training
Study NCT02948400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pedestrian safety training in pedestrian virtual environment
Description: pedestrian safety training
Study NCT04068532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT04068532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104
Description: Administered as specified in the treatment arm.
Study NCT02674659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session was held for around 30 minutes.
Study NCT02674659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
Study NCT05799456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Free glycosaminoglycan profiling
Description: Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.
Study NCT02321527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Protein-Type A Microspheres Injectable Suspension
Description: Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
Study NCT02321527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS)
Description: Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
Study NCT02321527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy + Radioactive Seed Placement
Description: Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
Study NCT02321527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
Study NCT01995916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Description: The Mindfulness Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
Study NCT01995916 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support Group
Description: The Social Support Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
Study NCT01334099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
Study NCT01334099 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External local radiation therapy
Description: One cycle of 2000cGy administered locally to one site over 5 days.
Study NCT04777513 — intervention group
Intervention type: PROCEDURE
Intervention: CCTA (Coronary Computed Tomography Angiography)
Description: Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
Study NCT04662515 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Study NCT04662515 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Study NCT04777513 — intervention group
Intervention type: PROCEDURE
Intervention: ICA (Invasive Coronary Angiography)
Description: Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
Study NCT04777513 — intervention group
Intervention type: PROCEDURE
Intervention: FFR (Fractional Flow Reserve)
Description: Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
Study NCT04662515 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Study NCT02911831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT04777513 — intervention group
Intervention type: DEVICE
Intervention: CNBP measurement
Description: Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
Study NCT04777513 — intervention group
Intervention type: DEVICE
Intervention: Cardiolens FFR-CT Pro
Description: Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.